Kennedy: GLP-1 drugs drove 3% U.S. obesity drop, Medicare price now $50
Source: Fox News · All Fox News reports
Unlock the full scoreboard
Letter grade, factuality, lean, and rationales — free with registration. No card required.
See grades free How grading works
Already have an account? Sign in. The full report below is free to read.
Embed this grade
Disagree with this grade or political lean?
Flagging is open to every reader with a free account. Sign in or create one to dispute this report.
Topics in this report
Summary
In a Fox News town hall clip, HHS Secretary Robert F. Kennedy Jr. responded to a question on GLP-1 weight-loss drugs (e.g., Ozempic). He acknowledged unknown long-term effects and common gastrointestinal side effects but stated the overall public-health impact has been "very, very good." He highlighted administration efforts that lowered Ozempic's price from $1,350 to enable Medicare access at $50 this summer, claimed U.S. prices are now below Europe's, cited a 3% drop in obesity rates over the past 12 months after 40 years of steady rise, and noted associated savings on chronic disease plus benefits to kidney, heart, and liver health.
Editorial Assessment
The broadcast accurately conveys Kennedy's perspective and notes real benefits and risks of GLP-1 drugs, which large studies link to cardiovascular, kidney, and liver improvements alongside GI side effects. However, viewers miss critical context on the obesity trend: Gallup data show a gradual 3.5-point decline from 39.9% in 2022 to 36.4% in 2026, with most of the drop occurring 2022-2024 before Kennedy took office. Fact-checks note he has repeatedly attributed the decline primarily to his "real food" agenda rather than the drugs whose expanded use closely tracks the timing of reductions in key age groups. The $1,350-to-$50 price narrative is broadly true for list prices and new Medicare pilot access but omits that negotiated net prices and European reimbursed costs have long been far lower, and the $50 copay applies to a temporary bridge program for select drugs and patients only. Overall, the segment presents an administration-friendly view that overstates recency and credit while underplaying the drugs' dominant role in recent progress.
Key Moments
Obesity rates in this country over the past 12 months have dropped by about 3% after 40 years of steady rise
Gallup shows total 3.5-point decline from 39.9% peak in 2022 to 36.4% in 2026; roughly two-thirds occurred 2022-2024 before current administration, per FactCheck.org analysis of the same data Kennedy cites elsewhere.
Brought the price down from $1,350 for Ozempic... Medicare patients will be able to get it for $50... Americans are now paying less than Europeans
List price was ~$1,350; Trump administration negotiated Medicare GLP-1 Bridge pilot at $50 copay starting July 2026 for select drugs/patients (temporary through 2027). European reimbursed prices have long been ~$80-170/month; recent U.S. net prices also declined but U.S. list prices remain higher.
Many people do not find them satisfactory because of side effects, a lot of gastrointestinal problems
Clinical trials and real-world data consistently show GI side effects (nausea, vomiting, diarrhea) in 40-65% of users; many discontinue.
Indications of benefits to kidney health, to heart health, liver health from some of these GLP drugs
Supported by cardiovascular outcome trials, FLOW kidney trial for semaglutide, meta-analyses showing reduced MACE, heart failure, kidney events, and improvements in liver fat/enzymes.
The overall impact on public health in this country has been a good one
Early data are promising on obesity, cardiometabolic outcomes and cost savings, but Kennedy himself notes unknown long-term impacts; observational studies also flag increased risks of GI, pancreatic, and other events.
Notable Concerns
- Distorted timeline and magnitude of obesity decline, implying a sharp recent drop under current policies
- Selective attribution of obesity gains primarily to administration actions rather than pre-existing GLP-1 uptake trend
- Price comparison omits nuances of list vs. net prices, insurance coverage, and the temporary nature of the $50 Medicare access
Sources Consulted
- Kennedy Distorts Stat in Celebrating Obesity Drop
- Obesity Rate Declining in U.S.
- In U.S., GLP-1 Usage Reaches New High
- Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
- GLP-1 Prescriptions Quadruple Since 2021 Alongside Decline In Obesity
- Mapping the effectiveness and risks of GLP-1 receptor agonists
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity